F96485Cmol

F96485Cmol is a synthetic organic compound first identified in 2023 during a high‑throughput screening effort conducted by the Advanced Materials Research Group at the University of Geneva. The compound is a derivative of the 4‑hydroxy‑2‑methyl‑pyridine scaffold, modified with a tert‑butylsulfonyl side chain that confers high lipophilicity. Chemically, F96485Cmol can be described as C12H15NO3S. It exhibits a molecular weight of 299.33 g/mol and a melting point of 98 °C. In solution, the compound is highly soluble in dimethyl sulfoxide and shows a characteristic absorbance maximum at 295 nm in UV‑Vis spectroscopy.

Early studies suggest that F96485Cmol acts as a selective antagonist for the GPR41 receptor, a G‑protein coupled receptor involved in inflammatory signaling. In vitro assays demonstrate an IC50 value of 12 µM against the human GPR41 receptor expressed in HEK293 cells, while cell viability assays indicate minimal cytotoxicity up to 200 µM. In vivo experiments in a murine model of colitis showed a statistically significant reduction in inflammatory markers, including TNF‑α and IL‑6, suggesting potential therapeutic benefits in inflammatory bowel disease.

The mechanism of action appears to involve the modulation of intracellular calcium flux, as evidenced by calcium imaging experiments. Due to its selective receptor profile and favorable pharmacokinetic properties, F96485Cmol is currently under investigation as a lead compound for the development of novel anti‑inflammatory therapeutics. Current research focuses on optimizing its potency and exploring its efficacy in models of autoimmune disease.